Categories: Market Research

Global Cervical Cancer Vaccine Market Size and Forecast 2024-2033|Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Novartis AG, Sanofi Pasteur,

Vaccine for vaccination, medical immunization for patient treatment from disease such as coronavirus, covid-19, cervical cancer, hpv, measles, meningitis, pertussis, pneumonia, tetanus, or typhoid

The Cervical Cancer Vaccine Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Cervical Cancer Vaccine Market:

https://www.thebusinessresearchcompany.com/report/cervical-cancer-vaccine-global-market-report

According to The Business Research Company’s Cervical Cancer Vaccine Global Market Report 2024, The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $82.74 billion in 2023 to $88.39 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to awareness campaigns and education, government initiatives and vaccination programs, increased incidence of cervical cancer, healthcare provider recommendations, global efforts for women’s health.

The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $117.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of vaccination coverage, integration into routine immunization programs, advancements in hpv testing and screening, global advocacy for hpv vaccination, rising focus on adolescent vaccination.. Major trends in the forecast period include incorporation of new adjuvants, integration of digital health platforms, innovative vaccine development, public-private partnerships, educational campaigns and advocacy.

The rising prevalence of cervical cancer cases is expected to propel the growth of the cervical cancer vaccine market going forward. Cervical cancer refers to a type of cancer that affects the lower part of the uterus (womb), the cervix, which connects to the upper part of the vagina. The rising number of cervical cancer cases is mostly driven by a lack of Human papillomavirus vaccines (HPV) vaccination, a lack of hygiene, and insufficient awareness and knowledge about cervical cancer. Cervical cancer vaccines are highly effective in preventing the development of cervical cancer by targeting the high-risk types of human papillomavirus (HPV). For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cervical cancer cases reported in the US was 13,960. Therefore, the rising number of cervical cancer cases is driving the growth of the cervical cancer vaccine market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=11886&type=smp

The cervical cancer vaccine market covered in this report is segmented –

1) By Type: Cervarix, Gardasil, Gardasil 9

2) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-Users: Hospital, Biotechnology Company, Academic And Research Organizations, Other End-Users

Product innovation has emerged as a key trend gaining popularity in the cervical cancer vaccine market. Leading market players are focusing their resources on developing groundbreaking products to fortify their market presence. For instance, in May 2022, GlaxoSmithKline, a UK-based pharmaceutical company, received approval from the National Medical Products Administration (NMPA) for its two-dose vaccine schedule, Cervarix, for girls ages nine to fourteen to prevent cervical cancer. With the granted approval, Cervarix has become the first two-dose imported HPV vaccine for this age group in mainland China.

The cervical cancer vaccine market report table of contents includes:

1. Executive Summary

2. Cervical Cancer Vaccine Market Characteristics

3. Cervical Cancer Vaccine Market Trends And Strategies

4. Cervical Cancer Vaccine Market – Macro Economic Scenario

5. Global Cervical Cancer Vaccine Market Size and Growth

26. South America Cervical Cancer Vaccine Market

27. Brazil Cervical Cancer Vaccine Market

28. Middle East Cervical Cancer Vaccine Market

29. Africa Cervical Cancer Vaccine Market

30. Cervical Cancer Vaccine Market Competitive Landscape And Company Profiles

Top Major Players: